168 related articles for article (PubMed ID: 752907)
1. [Bromocriptine in Parkinsonian syndromes. Results obtained in a group of patients treated for 8 months].
Quattrini A; Paggi A; Del Pesce M; Di Bella P
Riv Patol Nerv Ment; 1978; 99(3):150-63. PubMed ID: 752907
[TBL] [Abstract][Full Text] [Related]
2. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
Libman I; Gawel MJ; Riopelle RJ; Bouchard S
Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
[TBL] [Abstract][Full Text] [Related]
3. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
Grimes JD; Delgado MR
Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
[TBL] [Abstract][Full Text] [Related]
4. [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
Montastruc JL; Rascol O; Rascol A
Rev Neurol (Paris); 1990; 146(2):144-7. PubMed ID: 2181588
[TBL] [Abstract][Full Text] [Related]
5. [Experience with the use of parlodel in the treatment of Parkinson patients].
Stoliarova LG; Kadykov AS; Shvedkov VV; Pivovarova VM
Zh Nevropatol Psikhiatr Im S S Korsakova; 1986; 86(2):219-22. PubMed ID: 3705825
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
Brannan T; Yahr MD
Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
[TBL] [Abstract][Full Text] [Related]
7. "Long term evaluation of combined treatment of Parkinson disease with L-dopa, peripheral decarboxylase inhibitors and bromocreptine".
Caraceni T; Giovannini P; Girotti F; Parati E; Pederzoli M; Scigliano G
Ital J Neurol Sci; 1981 Dec; 2(4):337-42. PubMed ID: 7333824
[TBL] [Abstract][Full Text] [Related]
8. The addition of bromocriptine to long-term dopa therapy in Parkinson's disease.
Selby G
Clin Exp Neurol; 1989; 26():129-39. PubMed ID: 2701877
[TBL] [Abstract][Full Text] [Related]
9. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
Gawel M; Riopelle R; Libman I; Bouchard S
Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
[No Abstract] [Full Text] [Related]
10. [Long-term results of treatment of Parkinson's disease with bromocriptine and domperidone (author's transl)].
Agid Y; Quinn N; Lhermitte F
Rev Neurol (Paris); 1981; 137(1):49-51. PubMed ID: 7232966
[TBL] [Abstract][Full Text] [Related]
11. Treatment of parkinson's disease with bromocriptine.
Lieberman A; Kupersmith M; Estey E; Goldstein M
N Engl J Med; 1976 Dec; 295(25):1400-4. PubMed ID: 989885
[TBL] [Abstract][Full Text] [Related]
12. The Sydney multicentre study of Parkinson's disease. The first 18 months.
Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
[TBL] [Abstract][Full Text] [Related]
13. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
Admani AK; Verma S; Cordingley GJ; Harris RI
Pharmatherapeutica; 1985; 4(2):132-40. PubMed ID: 4059292
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
[TBL] [Abstract][Full Text] [Related]
15. Comparison between lergotrile and bromocriptine in parkinsonism.
Teychenne PF; Pfeiffer RF; Bern SM; McInturff D; Calne DB
Ann Neurol; 1978 Apr; 3(4):319-24. PubMed ID: 666273
[TBL] [Abstract][Full Text] [Related]
16. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
Eur Neurol; 1988; 28 Suppl 1():3-8. PubMed ID: 3378560
[TBL] [Abstract][Full Text] [Related]
17. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease.
Celesia GG; Wanamaker WM
Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661
[TBL] [Abstract][Full Text] [Related]
18. [Letter: Effect of bromocryptine on the fluctuations following dopa therapy. On-off phenomenon in parkinsonian patients].
Frattola L; Albizzati MG; Spano PF; Trabucchi M
Nouv Presse Med; 1976 Aug 28-Sep 4; 5(28):1761. PubMed ID: 958891
[No Abstract] [Full Text] [Related]
19. Low-dosage treatment in de novo patients with Parkinson's disease: a prospective study.
van der Drift JH
Adv Neurol; 1987; 45():529-34. PubMed ID: 3825731
[TBL] [Abstract][Full Text] [Related]
20. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
